Verona Pharma plc(VRNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VRNA Verona Pharma plc

Pre-Market Trading 01-10 06:01:58 EST

46.20

-3.35

-6.76%

盘前48.60

+2.40+5.19%

05:32 EST

High49.30	Low45.84	Vol1.69M
Open49.25	D1 Closing49.55	Amplitude6.97%
Mkt Cap3.78B	Tradable Cap2.32B	Total Shares81.83M
T/O79.88M	T/O Rate3.38%	Tradable Shares50.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"VRNA","market":"US","secType":"STK","nameCN":"Verona Pharma plc","latestPrice":46.2,"timestamp":1736370000000,"preClose":49.55,"halted":0,"volume":1693196,"hourTrading":{"tag":"盘前","latestPrice":48.6,"preClose":46.2,"latestTime":"05:32 EST","volume":235,"amount":11466.709850000001,"timestamp":1736505147347},"delay":0,"floatShares":50151549,"shares":81831169,"eps":-1.934086,"marketStatus":"Pre-Market Trading","change":-3.35,"latestTime":"01-10 06:01:58 EST","open":49.25,"high":49.295,"low":45.84,"amount":79880788.15392,"amplitude":0.069728,"askPrice":53.61,"askSize":22,"bidPrice":47.1,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.934086,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1736519400000},"marketStatusCode":1,"adr":1,"adrRate":8,"listingDate":1493265600000,"exchange":"NASDAQ","adjPreClose":46.2,"preHourTrading":{"tag":"盘前","latestPrice":48.6,"preClose":46.2,"latestTime":"05:32 EST","volume":235,"amount":11466.709850000001,"timestamp":1736505147347},"postHourTrading":{"tag":"盘后","latestPrice":46,"preClose":46.2,"latestTime":"19:55 EST","volume":26159,"amount":1210241.1587,"timestamp":1736384158122},"volumeRatio":0.8679340803846541,"impliedVol":0.6457,"impliedVolPercentile":0.224},"requestUrl":"/m/hq/s/VRNA","defaultTab":"news","newsList":[{"id":"1178664111","title":"Stock Track | Verona Pharma Soars 5.19% in Pre-market Trading on Analyst's Buy Rating for COPD Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1178664111","media":"Stock Track","labels":["movement"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1178664111?lang=en_us&edition=fundamental","pubTime":"2025-01-10 18:36","pubTimestamp":1736505376,"startTime":"0","endTime":"0","summary":"Verona Pharma plc  witnessed a significant pre-market surge of 5.19% on Friday, following a new Buy rating from Roth MKM analyst Boobalan Pachaiyappan for the company's Ohtuvayre drug, a potential treatment for chronic obstructive pulmonary disease .Pachaiyappan's Buy recommendation stems from his belief that Ohtuvayre represents a unique solution in the COPD market, citing its potential to address a significant unmet need and drive revenue growth for Verona Pharma. The analyst's positive outloo","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Verona Pharma Soars 5.19% in Pre-market Trading on Analyst's Buy Rating for COPD Drug","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["VRNA"],"gpt_icon":0},{"id":"2502855579","title":"Verona Pharma initiated with a Buy at Roth MKM","url":"https://stock-news.laohu8.com/highlight/detail?id=2502855579","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502855579?lang=en_us&edition=fundamental","pubTime":"2025-01-10 18:50","pubTimestamp":1736506226,"startTime":"0","endTime":"0","summary":"Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Verona Pharma (VRNA) with a Buy rating and $68 price target The firm says its investme...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/verona-pharma-initiated-with-a-buy-at-roth-mkm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/verona-pharma-initiated-with-a-buy-at-roth-mkm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","VRNA"],"gpt_icon":0},{"id":"2502853384","title":"Verona Pharma’s Ohtuvayre: Unique COPD Solution Drives Buy Rating Amid Market Potential and Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2502853384","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502853384?lang=en_us&edition=fundamental","pubTime":"2025-01-10 18:27","pubTimestamp":1736504867,"startTime":"0","endTime":"0","summary":"Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA). Boobalan Pachaiyappan has given his Buy ra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/verona-pharmas-ohtuvayre-unique-copd-solution-drives-buy-rating-amid-market-potential-and-revenue-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/verona-pharmas-ohtuvayre-unique-copd-solution-drives-buy-rating-amid-market-potential-and-revenue-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRNA","BK4007"],"gpt_icon":0},{"id":"2502493050","title":"Verona Pharma Plc : Piper Sandler Raises Target Price to $76 From $36","url":"https://stock-news.laohu8.com/highlight/detail?id=2502493050","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502493050?lang=en_us&edition=fundamental","pubTime":"2025-01-09 14:00","pubTimestamp":1736402405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250109:nFWN3O41RD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VRNA"],"gpt_icon":0},{"id":"2501771910","title":"Verona Pharma Price Target Raised to $57.00/Share From $44.00 by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2501771910","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501771910?lang=en_us&edition=fundamental","pubTime":"2025-01-08 23:45","pubTimestamp":1736351100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VRNA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2025 10:45 ET (15:45 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRNA"],"gpt_icon":0},{"id":"2501295107","title":"Verona Pharma Plc : Truist Securities Raises Target Price to $57 From $44","url":"https://stock-news.laohu8.com/highlight/detail?id=2501295107","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501295107?lang=en_us&edition=fundamental","pubTime":"2025-01-08 20:40","pubTimestamp":1736340033,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nFWN3O41L4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRNA","BK4007"],"gpt_icon":0},{"id":"2501741737","title":"Wells Fargo Sticks to Their Buy Rating for Verona Pharma (VRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2501741737","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501741737?lang=en_us&edition=fundamental","pubTime":"2025-01-08 18:24","pubTimestamp":1736331855,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on Verona Pharma (VRNA – Research Report), with a price target...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-their-buy-rating-for-verona-pharma-vrna?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-their-buy-rating-for-verona-pharma-vrna?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRNA"],"gpt_icon":0},{"id":"2501738270","title":"Verona Pharma to Report $36 Million in Q4 Net Product Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2501738270","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501738270?lang=en_us&edition=fundamental","pubTime":"2025-01-08 01:54","pubTimestamp":1736272458,"startTime":"0","endTime":"0","summary":"Verona Pharma  on Tuesday said it expects Q4 net product sales of $36 million on the back of the commercial launch of Ohtuvayre, a treatment for chronic obstructive pulmonary disease, a lung condition.Full-year 2024 net product sales are expected to be $42 million, the company said.Meanwhile, the company said it expected to report $400 million in cash and cash equivalents as of Dec. 31, 2024.Price: 48.95, Change: +4.14, Percent Change: +9.24","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VRNA"],"gpt_icon":0},{"id":"2501017592","title":"Truist Securities Raises Price Target on Verona Pharma to $57 From $44, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2501017592","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501017592?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:43","pubTimestamp":1736257423,"startTime":"0","endTime":"0","summary":"Truist Securities Raises Price Target on Verona Pharma to $57 From $44, Maintains Buy Rating","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VRNA"],"gpt_icon":0},{"id":"2501274782","title":"Verona Pharma Expects $400 Mln In Cash & Cash Equivalents As Of Dec 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2501274782","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501274782?lang=en_us&edition=fundamental","pubTime":"2025-01-07 19:26","pubTimestamp":1736249195,"startTime":"0","endTime":"0","summary":"Jan 7 (Reuters) - Verona Pharma PLC ::*VERONA PHARMA PLC - EXPECTS $400 MILLION IN CASH & CASH EQUIVALENTS AS OF DEC 31, 2024*VERONA PHARMA PLC - EXPECTS $36 MILLION IN Q4 NET PRODUCT SALES  RELATED T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nRSD9KvZKh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VRNA"],"gpt_icon":0},{"id":"2501271317","title":"Press Release: Verona Pharma Reports Strong Ohtuvayre(TM) Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2501271317","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501271317?lang=en_us&edition=fundamental","pubTime":"2025-01-07 19:00","pubTimestamp":1736247600,"startTime":"0","endTime":"0","summary":"Verona Pharma Reports Strong Ohtuvayre Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights. Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively. More than 3,500 unique prescribers and over 16,000 prescriptions filled in 2024 across a broad COPD population. Approximately 45% of Tier 1 HCPs prescribed Ohtuvayre. LONDON and RALEIGH, N.C., Jan. 07, 2025  -- Verona Pharma plc  , a biopharmaceutical company focused on respiratory diseases, announces preliminary unaudited net product sales for the fourth quarter and full year ended December 31, 2024, and provides a corporate update.\"We recorded net product sales of approximately $36 million in the fourth quarter and $42 million for full year 2024. While it is still early in the launch, feedback from HCPs and patients is consistently positive including robust refill rates, and increasing prescriber depth with over 150 HCPs prescribin","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","BK4099","TM","BK4555","VRNA","BK4585","03160"],"gpt_icon":1},{"id":"2501233260","title":"Truist Financial Remains a Buy on Verona Pharma (VRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2501233260","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501233260?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:16","pubTimestamp":1736165798,"startTime":"0","endTime":"0","summary":"In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Verona Pharma (VRNA – Research Report). The company’s shares ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-remains-a-buy-on-verona-pharma-vrna?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-remains-a-buy-on-verona-pharma-vrna?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","VRNA"],"gpt_icon":0},{"id":"2494862821","title":"European Equities Traded in the US as American Depositary Edge Higher in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2494862821","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494862821?lang=en_us&edition=fundamental","pubTime":"2024-12-27 00:07","pubTimestamp":1735229238,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were slightly higher late Thursday morning, edging 0.10% higher to 1,298.82 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by furniture maker Natuzzi  and medical device maker EDAP TMS , which climbed 18% and 7.3% respectively. They were followed by telecommunications company VEON  and biopharmaceutical company Genfit , which were up 2.5% each.The decliners from continental Europe were led by biotech firm Evaxion Biotech  and biopharmaceutical company DBV Technologies , which dropped 2.8% and 2.6% respectively. They were followed by accommodations booking company trivago  and 3D printer company Materialise , which were off 0.7% each.From the UK and Ireland, the gainers were led by biotech firm Autolus Therapeutics  and biopharmaceutical company Verona Pharma , which increased 2.2% and 2% respectively. They were followed by biopharmaceutical companies Bicycle Therapeutics  and TC Biophar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VEON","BCYC","LU0950373646.USD","AUTL","BK4546","BK4023","VRNA","BK4077","BK4082","BK4095","BK4132","TRIB","EVAX","AFG","TCBP","MTLS","AKTX","ADAP","LU0823431647.USD","BK4007","TRVG","DBVT","BK4107","NTZ","BK4139","EDAP","GNFT","SLN","BK4117","LU0823431563.USD"],"gpt_icon":0},{"id":"2493381767","title":"European Equities Traded in the US as American Depositary Receipts Start Week Down Slightly in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2493381767","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493381767?lang=en_us&edition=fundamental","pubTime":"2024-12-24 00:04","pubTimestamp":1734969897,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were trending slightly lower late Monday morning, declining 0.16% to 1,278.01 on the S&P Europe Select ADR Index.From continental Eur","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","LU0084288595.USD","NTZ","BK4082","AFG","NVO.AU","BK4023","BK4585","EDAP","BK4009","BK4007","DAVA","BK4139","CRTO","SQNS","BK4142","NVO","SLN","VRNA","IE00BFMHRM44.USD","TCBP","BK4077","CUK","LU1093756168.USD","BK4107","BK4134","BK4532","BK7104","BK4546","AKTX","IE00BZ1G4Q59.USD","BK4117","LU0154236417.USD","AUTL","MREO","DAVA.AU","IE00BKVL7J92.USD","LU0648005311.SGD","BK4588","BK4599","BK4141","LU1093756325.SGD","BK4095","MTLS","TRVG","EVAX"],"gpt_icon":1},{"id":"2493759067","title":"Truist Financial Releases a Buy Rating on Verona Pharma (VRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2493759067","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493759067?lang=en_us&edition=fundamental","pubTime":"2024-12-23 20:15","pubTimestamp":1734956150,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $42.02. According to TipRank...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-releases-a-buy-rating-on-verona-pharma-vrna-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-releases-a-buy-rating-on-verona-pharma-vrna-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRNA"],"gpt_icon":0},{"id":"2492994616","title":"European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2492994616","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492994616?lang=en_us&edition=fundamental","pubTime":"2024-12-17 00:10","pubTimestamp":1734365429,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts started the week off higher late Monday morning, rising 0.32% to 1,343.34 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical companies argenx  and Grifols , which rose 4.3% and 3.9% respectively. They were followed by medical device maker EDAP TMS  and pharmaceutical company Ascendis Pharma , which increased 3.1% and 2.7% respectively.The decliners from continental Europe were led by biotech firm Evaxion Biotech  and biopharmaceutical company DBV Technologies , which fell 18% and 3.1% respectively. They were followed by biopharmaceutical company Cellectis  and petroleum refiner Equinor , which were down 2.8% and 2.4% respectively.From the UK and Ireland, the gainers were led by biopharmaceutical company Bicycle Therapeutics  and biotech firm Autolus Therapeutics , which advanced 8.6% and 5% respectively. They were followed by biopharmaceutical companies Verona Pharma  a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1829250122.USD","BK4117","VRNA","EQNR","PUK","ARGX","LU0162691827.USD","BK4201","CLLS","BK4007","BK4505","ASND","EVAX","LU0072461881.USD","BK4107","AUTL","AFG","BP","LU1162221912.USD","LU0320765992.SGD","DBVT","LU0320765646.SGD","MREO","LU0889565916.HKD","BK4139","BCYC","BK4082","BK4585","AMRN","LU0109394709.USD","BK4162","GRFS","EDAP","BK4588","TRIB"],"gpt_icon":0},{"id":"2491918372","title":"European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Down 1.5% for Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2491918372","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491918372?lang=en_us&edition=fundamental","pubTime":"2024-12-14 00:10","pubTimestamp":1734106214,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were lower late Friday morning, declining 0.25% to 1,337.43 on the S&P Europe Select ADR Index, which is down 1.5% for the week.From ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ING","ING.AU","DEO","AKTX","BCYC","VRNA","TCBP","BK4095","BK4585","BK4107","BDRX","BK4169","BK4007","BK4591","SAN","NTZ","ADAP","BBVA","BK4515","BK4588","BK4139","BK4521","BK4020","AFG","BK7505","BK4023","BK7141","BK7142","ERIC","MTLS","DGE.UK","BK4207","BK4546","BK4554","DBVT","EVAX","BK4117","NCNA","SAN.AU"],"gpt_icon":1},{"id":"2488603261","title":"European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2488603261","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488603261?lang=en_us&edition=fundamental","pubTime":"2024-12-03 00:16","pubTimestamp":1733156163,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts kicked off the week trending lower late Monday morning, declining 0.37% to 1,326.63 on the S&P Europe Select ADR Index.From continent","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4142","EVAX","LU1829250122.USD","BK4139","AFG","BK4515","BK4561","BK4599","SQNS","BK4505","BK4007","BK4588","LU2129689431.USD","TRIB","LU1093756168.USD","OPRA","BK4023","BK4141","LU0154236417.USD","LU2129689514.USD","BK4554","LU2237443465.HKD","NTZ","LU2237443382.USD","BK4082","TTE","NVO.AU","AKTX","LU0320765646.SGD","LU0162691827.USD","NVO","LU2237443978.SGD","CUK","BK7104","BK4095","BK4591","LU0072461881.USD","SLN","BP","BK4201","ERIC","LU1093756325.SGD","GNFT","TCBP","BK4107","MREO","VRNA","LU2237443622.USD","IE00BZ1G4Q59.USD","LU2237443895.HKD"],"gpt_icon":1},{"id":"2484924768","title":"European Equities Traded in the US as American Depositary Decline Slightly in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2484924768","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484924768?lang=en_us&edition=fundamental","pubTime":"2024-11-20 00:18","pubTimestamp":1732033088,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were edging lower Tuesday morning, declining 0.14% to 1,308.28 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm BioNTech  and internet advertising company Criteo , which rose 5% and 4.6% respectively. They were followed by medical device maker EDAP TMS  and biopharmaceutical company DBV Technologies , which were up 3.4% each.The decliners from continental Europe were led by furniture maker Natuzzi  and biopharmaceutical company Grifols , which fell 8.1% and 7.1% respectively. They were followed by semiconductor company Sequans Communications  and financial services company Banco Santander , which lost 3.1% and 2% respectively.From the UK and Ireland, the gainers were led by biopharmaceutical companies Verona Pharma  and Adaptimmune Therapeutics , which climbed 7.6% and 5.4% higher respectively. They were followed by biopharmaceutical company Amarin  and utility company Nat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","BK4139","AFG","ADAP","BK4521","SQNS","PUK","BK4505","BK4007","BK4588","BK4568","SAN","BK4548","BK7142","BK4141","NTZ","DBVT","BK4082","BK4117","BK4207","BK4532","AKTX","BK4009","BK4585","EDAP","SLN","BK4095","GRFS","BK4162","AMRN","BNTX","IE00BFMHRM44.USD","BK4107","MREO","VRNA","BK4208","BK4551","CRTO","SAN.AU","NGG"],"gpt_icon":0},{"id":"2484499598","title":"Verona Pharma Announces December 2024 Investor Conference Participation","url":"https://stock-news.laohu8.com/highlight/detail?id=2484499598","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484499598?lang=en_us&edition=fundamental","pubTime":"2024-11-19 15:00","pubTimestamp":1731999600,"startTime":"0","endTime":"0","summary":"Piper Sandler 36th Annual Healthcare ConferenceDate: Tuesday, December 3, 2024Time: 12:00 p.m. ET / 5:00 p.m. GMTLocation: New York, NY. 7th Annual Evercore HealthCONx ConferenceDate: Wednesday, December 4, 2024Time: 3:00 p.m. ET / 8:00 p.m. GMTLocation: Miami, FL. Victoria Stewart, Senior Director of Investor Relations and Communications","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/DlGeVM0kSSxRBZfsvBhMdw--~B/aD01ODE7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/7a37880ab415a7f66acc4aa9a219cd8f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/DlGeVM0kSSxRBZfsvBhMdw--~B/aD01ODE7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/7a37880ab415a7f66acc4aa9a219cd8f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verona-pharma-announces-december-2024-070000473.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VRNA","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.veronapharma.com","stockEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":0.1493},{"period":"3month","weight":0.4727},{"period":"6month","weight":1.219},{"period":"1year","weight":1.4535},{"period":"ytd","weight":-0.0052}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0251},{"period":"3month","weight":0.0232},{"period":"6month","weight":0.0527},{"period":"1year","weight":0.244},{"period":"ytd","weight":0.0058}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.072248},{"month":2,"riseRate":0.428571,"avgChangeRate":0.024379},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.014175},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.063776},{"month":5,"riseRate":0.5,"avgChangeRate":-0.026344},{"month":6,"riseRate":0.25,"avgChangeRate":-0.037719},{"month":7,"riseRate":0.625,"avgChangeRate":0.1404},{"month":8,"riseRate":0.5,"avgChangeRate":0.11834},{"month":9,"riseRate":0.375,"avgChangeRate":0.007343},{"month":10,"riseRate":0.25,"avgChangeRate":-0.009258},{"month":11,"riseRate":0.375,"avgChangeRate":0.006476},{"month":12,"riseRate":0.75,"avgChangeRate":0.295436}],"exchange":"NASDAQ","name":"Verona Pharma plc","nameEN":"Verona Pharma plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Verona Pharma plc(VRNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Verona Pharma plc(VRNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Verona Pharma plc,VRNA,Verona Pharma plc股票,Verona Pharma plc股票老虎,Verona Pharma plc股票老虎国际,Verona Pharma plc行情,Verona Pharma plc股票行情,Verona Pharma plc股价,Verona Pharma plc股市,Verona Pharma plc股票价格,Verona Pharma plc股票交易,Verona Pharma plc股票购买,Verona Pharma plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Verona Pharma plc(VRNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Verona Pharma plc(VRNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction